I'm Obsessed With the Way These Viral Vitamin Gummy Bears Helped My Digestion & They're *Finally* on Sale
Anyone who knows me knows that using the bathroom can be challenging for me. There are moments when I struggle to have a bowel movement so much that I can count on one hand how many I have in a week. Yeah, it's that bad. While there are plenty of reasons that have contributed to my struggles and even more products that promise to help, nothing has done the job quite like these comprehensive gummy bears (I know, surprising, right?) And the best part is, they're on sale this week.
More from SheKnows
Skincare Enthusiasts Swear This Unique Overnight Mask Is the Secret to a 'Youthful Glow With Minimal Effort' & It's $13 Today
Today's Top Deals
How Do You Raise Good Kids in Terrifying Times? 'Hello, Cruel World' Author Melinda Wenner Moyer Has Ideas
Think Spring! Target Just Added Tons of Gorgeous New Patio Items
Target Is Having a Can't-Miss Spring Sandal Sale for Circle Members
Now, I know you must be thinking that gummy bears, of all things, really couldn't be the solution to my constipation and lack of bowel movements. However, truthfully, no other laxative has worked as well as Grüns. And maybe it's because they did more for me than aid in having a bowel movement. Grüns is a total multivitamin that's said to 'fill in the nutrition gaps.' It claims to support various aspects of health, including immunity, energy, brain health, and gut health. It's made with prebiotics that 'stimulate the growth of good bacteria to improve nutrient absorption, digestion, and the immune system,' according to the brand.
BEST MULTI-VITAMIN GUMMIES 2025
$48 $80 40% off
Buy Now
And I'll admit, the first time I heard about these, I was ready to say it was total bull. I mean, a gummy bear vitamin? How juvenile! But one day, I was given a bag full of them and decided to give a pack a try because why not? I've already tried everything else. Within hours, I was able to have a bowel movement with ease, which is very important for someone who typically feels difficulty with laxatives. I was so shocked at how easy it was, but I still thought it was a fluke. So, I decided to put it to the test. For an entire week, I ate a pack of Grüns a day, and each day, I had a bowel movement. Then, the following week, when I didn't eat a pack a day, my body went back to (ir)regularly scheduled programming where I was going every other day (if that).
Now, I will say I can't necessarily speak to the other benefits because that's not what I was focused on. And since I'm not a doctor, it would be something you should discuss with yours and see for yourself if you have a similar experience. And the only negative I do have about these bears is that they're expensive! Call me cheap, but $80 for a big bag of gummy bears is steep, even for the sugar fiend in me. Since they're so pricey, I haven't restocked them, and as you can imagine, I'm back to being irregular. But now that they're on sale, I'm definitely stocking up on as many bags as my account will allow.
Right now, you can save up to 43% off your first Grüns subscription order and save $20 off every bag after that. You can snag your first bag here or on Grüns.co this week only.
Before you go, check out our below:
More Top Deals from SheKnows
Is Walmart+ Worth It?
Giada De Laurentiis' Newest Cookbook Is Packed With Italian Super Food Recipes
Stanley Tumblers Now Come With New Leakproof Lids & Customers Are Raving About Them
Best of SheKnows
72 Costco Products That Have Gained a Cult Following for a Good Reason
15 Ultra-Hydrating Tinted Lip Balms Highly Recommended by Amazon Shoppers — All Under $15
Marilyn Monroe Used These Beauty & Skincare Products — Now on Amazon Starting at Only $5
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
UnitedHealth appoints Wayne DeVeydt as CFO in another management shake-up
(Reuters) -UnitedHealth said on Thursday it will replace its finance chief John Rex with an external hire, Wayne DeVeydt, adding to the management changes at the health insurer that has been struggling to control its medical costs. Rex, who has been handling the role since 2016, will continue as a strategic advisor to the CEO, with the changes effective September 2. DeVeydt was most recently managing director and operating partner at Bain Capital, and was also the finance chief of UnitedHealth's rival Elevance , then called Anthem, between 2007 and 2016. The largest U.S. health insurer had seen an abrupt departure of Andrew Witty as CEO in May, with Stephen Hemsley replacing him following struggles with elevated medical costs that were also seen in the rest of the industry. Hemsley is under pressure to regain investor trust as the company faces financial struggles and reputational damage that surfaced after the then-CEO of its health insurance unit was gunned down on a New York City street in December. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
ResMed (NYSE:RMD) Surprises With Q2 Sales
Medical device company ResMed (NYSE:RMD) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts' consensus estimates. Is now the time to buy ResMed? Find out in our full research report. ResMed (RMD) Q2 CY2025 Highlights: Revenue: $1.35 billion vs analyst estimates of $1.33 billion (10.2% year-on-year growth, 1.3% beat) Adjusted EPS: $2.55 vs analyst estimates of $2.48 (3% beat) Adjusted EBITDA: $542.9 million vs analyst estimates of $494.7 million (40.3% margin, 9.8% beat) Operating Margin: 33.7%, up from 31.2% in the same quarter last year Free Cash Flow Margin: 37.7%, up from 33.9% in the same quarter last year Constant Currency Revenue rose 9% year on year (10% in the same quarter last year) Market Capitalization: $40.61 billion 'Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem,' said Resmed's Chairman and CEO, Mick Farrell. Company Overview Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, ResMed's sales grew at a decent 11.7% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ResMed's annualized revenue growth of 10.4% over the last two years is below its five-year trend, but we still think the results were respectable. ResMed also reports sales performance excluding currency movements, which are outside the company's control and not indicative of demand. Over the last two years, its constant currency sales averaged 10.3% year-on-year growth. Because this number aligns with its normal revenue growth, we can see that ResMed has properly hedged its foreign currency exposure. This quarter, ResMed reported year-on-year revenue growth of 10.2%, and its $1.35 billion of revenue exceeded Wall Street's estimates by 1.3%. Looking ahead, sell-side analysts expect revenue to grow 8.1% over the next 12 months, a slight deceleration versus the last two years. Despite the slowdown, this projection is noteworthy and suggests the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin ResMed has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 29%. Analyzing the trend in its profitability, ResMed's operating margin rose by 4.5 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 5.9 percentage points on a two-year basis. These data points are very encouraging and shows momentum is on its side. This quarter, ResMed generated an operating margin profit margin of 33.7%, up 2.6 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. ResMed's EPS grew at a spectacular 14.9% compounded annual growth rate over the last five years, higher than its 11.7% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. We can take a deeper look into ResMed's earnings to better understand the drivers of its performance. As we mentioned earlier, ResMed's operating margin expanded by 4.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, ResMed reported adjusted EPS at $2.55, up from $2.08 in the same quarter last year. This print beat analysts' estimates by 3%. Over the next 12 months, Wall Street expects ResMed's full-year EPS of $9.55 to grow 8.6%. Key Takeaways from ResMed's Q2 Results It was good to see ResMed narrowly top analysts' revenue expectations this quarter. We were also happy its constant currency revenue narrowly outperformed Wall Street's estimates. Overall, this print had some key positives. The stock remained flat at $270.94 immediately following the results. So do we think ResMed is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
28 minutes ago
- New York Times
Childhood Vaccination Rates Have Dropped Again, C.D.C. Data Shows
New federal data shows that vaccination rates among American children entering kindergarten fell during the 2024-25 school year, extending a worrying trend that began during the Covid-19 pandemic. The percentage of children granted exemptions from vaccines has also risen sharply over the past decade. The statistics, released Thursday by the Centers for Disease Control and Prevention, provide a sobering explanation for the resurgence of childhood diseases across the United States. Measles has sickened more people this year than in any year since the virus was declared eliminated in 2000, in large part because of a multistate outbreak that began in West Texas and has led to three deaths. 'The more these rates continue to drop, the more danger we're in of seeing outbreaks like we saw in Texas,' said Dr. Adam Ratner, a pediatric infectious disease expert in New York City. The report comes at a time when public health experts are particularly concerned about childhood vaccinations because of increasing skepticism of the shots, including among top health officials. Robert F. Kennedy Jr., the health secretary, has questioned, without scientific basis, the safety of many childhood vaccines, including those for measles, hepatitis B and polio. In June, a panel of vaccine advisers installed by Mr. Kennedy announced that they would closely scrutinize the immunization schedules for children and adolescents. Mr. Kennedy's appointees have also restricted access to the Covid-19 vaccine for healthy pregnant women and children. The messaging from Mr. Kennedy's office seems 'specifically designed to sow distrust in vaccines,' said Dr. Sean O'Leary, chair of the infectious disease committee for the American Academy of Pediatrics. Source: Centers for Disease Control and Prevention Note: Data is incomplete for Mississippi, Montana and West Virginia. Source: Centers for Disease Control and Prevention Want all of The Times? Subscribe.
